JPWO2021165405A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021165405A5 JPWO2021165405A5 JP2022550755A JP2022550755A JPWO2021165405A5 JP WO2021165405 A5 JPWO2021165405 A5 JP WO2021165405A5 JP 2022550755 A JP2022550755 A JP 2022550755A JP 2022550755 A JP2022550755 A JP 2022550755A JP WO2021165405 A5 JPWO2021165405 A5 JP WO2021165405A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- aminolevulinic acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- -1 Artemisinin compound Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 5
- 229960004191 artemisinin Drugs 0.000 claims 5
- 229930101531 artemisinin Natural products 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 208000005017 glioblastoma Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- HJBHOJZDRYXROF-UHFFFAOYSA-N 5-amino-2-methyl-4-oxopentanoic acid Chemical compound OC(=O)C(C)CC(=O)CN HJBHOJZDRYXROF-UHFFFAOYSA-N 0.000 claims 4
- 229960002749 aminolevulinic acid Drugs 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 229960002247 lomustine Drugs 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- JIRRPAZFOGASCY-ZTNVNUCQSA-N (2r,3s,5s)-5-(6-aminopurin-9-yl)-5-chloro-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@]1(Cl)C[C@H](O)[C@@H](CO)O1 JIRRPAZFOGASCY-ZTNVNUCQSA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- YHSMSRREJYOGQJ-UHFFFAOYSA-N 5-nonyloxytryptamine Chemical compound CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1 YHSMSRREJYOGQJ-UHFFFAOYSA-N 0.000 claims 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims 1
- 229960004287 clofazimine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005672 electromagnetic field Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 claims 1
- 229960004500 flubendazole Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims 1
- 238000009217 hyperthermia therapy Methods 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 229960000227 nisoldipine Drugs 0.000 claims 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960005212 vindesine sulfate Drugs 0.000 claims 1
Claims (15)
- a)アルテミシニン化合物(1)、またはその薬学的に許容可能な塩、共結晶、もしくは溶媒和物;
b)5-アミノレブリン酸(2)、メチル-5-アミノレブリン酸(2b)、またはその薬学的に許容可能な塩、もしくは溶媒和物;および
c)少なくとも一つの化学療法剤、または少なくとも一つの抗-膠芽腫薬、
を含む医薬組成物。 - 前記抗-膠芽腫薬は、テモゾロミド、デキサメタゾン、ロムスチン、メトトレキサート、エベロリムス、カルムスチン、シクロホスファミド、シスプラチン、カルボプラチン、5-フルオロウラシル、トリプトリド、ホモハリングトニン、ダクチノマイシン、ドキソルビシン、エピルビシン、イダルビシン、リバビリン、トポテカン、フルベンダゾール、イトラコナゾール、硫酸ビンデシン、セリバスタチン、ビンクリスチン、ビノレビン、ニソルジピン、デオキシアデノシン、クロロ-2’-デオキシアデノシン、5-ノニルオキシトリプタミン、2(1H)-ピリミジノン、ピタバスタチン、セルトラリン、イリノテカン、クロファジミン、およびドセタキセルからなる群から選択される、請求項1または請求項2に記載の医薬組成物。
- 前記アルテミシニン化合物(1)と、前記5-アミノレブリン酸(2)または前記メチル-5-アミノレブリン酸(2b)とのモル比は、1:5~1:5000の範囲である、請求項1~請求項3のいずれか一項に記載の医薬組成物。
- 前記医薬組成物は、薬学的に許容可能な担体、賦形剤および/または希釈剤を更に含む、請求項1~請求項4のいずれか一項に記載の医薬組成物。
- 前記少なくとも一つの抗-膠芽腫薬は、テモゾロミド、ロムスチン、シスプラチン、および5-フルオロウラシル、からなる群から選択される、請求項1~請求項5のいずれか一項に記載の医薬組成物。
- 医薬において使用するための請求項1~請求項7のいずれか一項に記載の医薬組成物。
- 造血癌、脳癌、膵臓癌、肝臓癌、乳癌および肺癌から選択される癌の予防および/または治療に使用するための、請求項1~請求項7のいずれか一項に記載の医薬組成物。
- 前記医薬組成物は、錠剤、カプセル、シロップ、溶液、懸濁液、エマルション、またはゲルの形態である、請求項8または請求項9に記載の医薬組成物。
- 前記医薬組成物は、経口、髄腔内、静脈内、皮下、非経口適用によって、または吸入によって投与される、請求項7~請求項10のいずれか一項に記載の医薬組成物。
- 前記アルテミシニン化合物(1)は、1日につき体重当たり0.01~100mg/kgの範囲で投与され、前記5-アミノレブリン酸または前記メチル-5-アミノレブリン酸は、1日につき体重当たり0.01~200mg/kgの範囲で投与される、請求項7~請求項11のいずれか一項に記載の医薬組成物。
- 前記少なくとも一つの抗-膠芽腫薬は、1日につき体重当たり0.01~100mg/kgの範囲で投与される、請求項7~請求項12のいずれか一項に記載の医薬組成物。
- 前記脳癌は、前神経(PN)、間葉系(MES)、および古典的(CL)膠芽腫のサブタイプから選択される、請求項9に記載の医薬組成物。
- 造血癌、脳癌、膵臓癌、肝臓癌、乳癌および肺癌から選択される癌の前記予防および/または治療は、放射線療法、免疫療法、電磁場療法、温熱療法、化学療法、癌免疫療法、および/または任意の他の小分子に基づく療法と組み合わせて行われる、請求項9に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20158341.6 | 2020-02-19 | ||
EP20158341.6A EP3868372A1 (en) | 2020-02-19 | 2020-02-19 | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
PCT/EP2021/054039 WO2021165405A1 (en) | 2020-02-19 | 2021-02-18 | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023514426A JP2023514426A (ja) | 2023-04-05 |
JPWO2021165405A5 true JPWO2021165405A5 (ja) | 2024-02-26 |
Family
ID=69779738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022550755A Pending JP2023514426A (ja) | 2020-02-19 | 2021-02-18 | アルテミシニン化合物、5-アミノレブリン酸またはメチル-5-アミノレブリン酸、および化学療法剤の医薬配合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230121771A1 (ja) |
EP (2) | EP3868372A1 (ja) |
JP (1) | JP2023514426A (ja) |
KR (1) | KR20220143097A (ja) |
CN (1) | CN114786661A (ja) |
AU (1) | AU2021222339A1 (ja) |
BR (1) | BR112022014692A2 (ja) |
CA (1) | CA3165208A1 (ja) |
DK (1) | DK3989961T3 (ja) |
FI (1) | FI3989961T3 (ja) |
IL (1) | IL294856A (ja) |
PL (1) | PL3989961T3 (ja) |
PT (1) | PT3989961T (ja) |
WO (1) | WO2021165405A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4252001A1 (en) * | 2020-11-30 | 2023-10-04 | Sonalasense, Inc. | Metabolic targeting of low grade tumors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2157424T3 (es) | 1995-03-10 | 2001-08-16 | Photocure Asa | Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia. |
GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
US10925963B2 (en) * | 2015-06-22 | 2021-02-23 | Washington University | Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor |
CN106527586B (zh) * | 2016-11-04 | 2019-09-06 | 吉林省北方医药有限责任公司 | 一种移动终端设备 |
CN108570089B (zh) * | 2017-04-28 | 2019-10-29 | 云白药征武科技(上海)有限公司 | 双氢青蒿素-甾体结合物及其制备方法和应用 |
GB201800736D0 (en) * | 2018-01-17 | 2018-02-28 | St Georges Hospital Medical School | Combination therapy for treatment of leukemia |
CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备治疗肿瘤的药物中的应用 |
-
2020
- 2020-02-19 EP EP20158341.6A patent/EP3868372A1/en active Pending
-
2021
- 2021-02-18 IL IL294856A patent/IL294856A/en unknown
- 2021-02-18 CN CN202180007033.7A patent/CN114786661A/zh active Pending
- 2021-02-18 EP EP21705541.7A patent/EP3989961B1/en active Active
- 2021-02-18 WO PCT/EP2021/054039 patent/WO2021165405A1/en active Application Filing
- 2021-02-18 FI FIEP21705541.7T patent/FI3989961T3/fi active
- 2021-02-18 DK DK21705541.7T patent/DK3989961T3/da active
- 2021-02-18 PL PL21705541.7T patent/PL3989961T3/pl unknown
- 2021-02-18 AU AU2021222339A patent/AU2021222339A1/en active Pending
- 2021-02-18 JP JP2022550755A patent/JP2023514426A/ja active Pending
- 2021-02-18 PT PT217055417T patent/PT3989961T/pt unknown
- 2021-02-18 KR KR1020227032196A patent/KR20220143097A/ko active Search and Examination
- 2021-02-18 BR BR112022014692A patent/BR112022014692A2/pt unknown
- 2021-02-18 CA CA3165208A patent/CA3165208A1/en active Pending
- 2021-02-18 US US17/801,021 patent/US20230121771A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5709354B2 (ja) | mTOR阻害剤投与によるがん患者の治療 | |
JP5113038B2 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
TW201513864A (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
JP2003533485A5 (ja) | ||
US20170232017A1 (en) | Treatment of cancer | |
JP2009536956A (ja) | 抗癌治療法 | |
JP2021512110A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
US10080807B2 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | |
KR100812693B1 (ko) | 항종양 효과 증강제 및 항종양제 | |
ES2393398T3 (es) | Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer | |
JP2021523169A (ja) | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
KR101572529B1 (ko) | 암 치료를 위한 육산화사비소의 병용요법 | |
JPWO2019152530A5 (ja) | ||
WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
US20090041715A1 (en) | Epothilone Combinations | |
TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
JPWO2021165405A5 (ja) | ||
US20090281105A1 (en) | Radiotherapy enhancer | |
WO2013137433A1 (ja) | 3剤を組み合わせた新規な抗腫瘍剤 | |
JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
JP2020528418A (ja) | BET阻害剤及びBcl−2阻害剤を用いた併用療法 | |
JPWO2019147615A5 (ja) | ||
JP2011514356A5 (ja) | ||
US20220395575A1 (en) | Combination therapy with protein kinase b activation inhibitor to treat cancer | |
JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |